Journal «Angiology and Vascular Surgery» • 

2019 • VOLUME 25 • №4

State of the art of stem cell therapy for ischaemic cardiomyopathy
Part 2

Milica Maslovaric1, Nikola Fatic2, Emilija Delević3

1) Prona-Montenegrin Science Promotion Foundation,
2) Department of Vascular Surgery, Clinical Centre of Montenegro,
3) Medical Faculty in Podgorica, University of Montenegro, Podgorica, Montenegro

Ischemic cardiomyopathy is becoming a leading cause of morbidity and mortality in the whole world. Stem cell-based therapy is emerging as a promising option for treatment of ischemic cardiomyopathy. Several stem cell types, including cardiac-derived stem cells, bone marrow-derived stem cells, mesenchymal stem cells, skeletal myoblasts, CD34+ and CD133+ stem cells have been used in clinical trials. Clinical effects mostly depend on transdifferentiation and paracrine factors. One important issue is that a low survival and residential rate of transferred stem cells blocks the effective advances in cardiac improvement. Many other factors associated with the efficacy of cell replacement therapy for ischemic cardiomyopathy mainly including the route of delivery, the type and number of stem cell infusion, the timing of injection, patient’s physical conditions, the particular microenvironment onto which the cells are delivered, and clinical conditions remain to be addressed. Here we provide an overview of modern methods of stem cell delivery, types of stem cells and discuss the current state of their therapeutic potential.

KEY WORDS: mesenchymal stem cells, cardiac-derived stem cells, skeletal myoblasts, bone marrow-derived stem cells, intramyocardial injection, transvascular cell delivery.

P. 17-26

Full text

« Back